1. Signaling Pathways
  2. Immunology/Inflammation
  3. CD38
  4. CD38 Inhibitor

CD38 Inhibitor

CD38 Inhibitors (10):

Cat. No. Product Name Effect Purity
  • HY-N0640
    Kuromanin chloride
    Inhibitor 99.50%
    Kuromanin chloride (Chrysontemin) is derived from mulberry leaves and has the effect of increasing blood sugar concentration and maintaining lipid metabolism balance to reduce obesity. Kuromanin chloride can inhibit CD38 enzymatic activities.
  • HY-150508
    MK-0159
    Inhibitor 99.72%
    MK-0159 is an orally active, potent and selective CD38 inhibitor, with IC50 values of 22, 3, and 70 nM for human, mouse and rat CD38, respectively. MK-0159 also shows good microsomal stability for human and rodent liver microsomes. MK-0159 increases NAD+ (nicotinamide adenine dinucleotide) and reduces ADPR (adenosine diphosphate ribose) in whole blood and heart.
  • HY-156120
    CD38 inhibitor 3
    Inhibitor
    CD38 inhibitor 3 (compound 1) is a potent CD38 inhibitor (IC50=11 nM). CD38 inhibitor 3 can promote mitochondrial biogenesis, reduce lactate levels, and increase NAD+ content and Nrf2 expression. In a model of mitochondrial myopathy, CD38 inhibitor 3 increases muscle contraction/development and improves exercise tolerance in Pus1-/- mice.
  • HY-P99616
    Felzartamab
    Inhibitor 99.34%
    Felzartamab (MOR-202) is a human monoclonal antibody that targets CD38 and can be used in multiple myeloma research.
  • HY-134358A
    Ara-F-NAD+ sodium
    Inhibitor
    Ara-F-NAD+ sodium is an arabino analogue of NAD+. Ara-F-NAD+ sodium is a potent, reversible and slow-binding CD38 NADase inhibitor.
  • HY-P99730
    Mezagitamab
    Inhibitor
    Mezagitamab (TAK-079) is a IgG1λ anti-CD38 monoclonal antibody. Mezagitamab depletes tumor cells expressing CD38 through antibody and complement dependent cytotoxicity. Mezagitamab has potential application in relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP).
  • HY-P99744
    Modakafusp alfa
    Inhibitor
    Modakafusp alfa (TAK-573) is a humanized, anti-CD38 IgG4 monoclonal antibody fused to 2 attenuated IFNα2b molecules. Modakafusp alfa can be used in the research of multiple myeloma.
  • HY-134358
    Ara-F-NAD+
    Inhibitor
    Ara-F-NAD+ is an arabino analogue of NAD+. Ara-F-NAD+ is a potent, reversible and slow-binding CD38 NADase inhibitor.
  • HY-119648A
    (E/Z)-CCR-11
    Inhibitor 98.00%
    (E/Z)-CCR-11 (Comp 12) is a selective CD38 inhibitor, with an IC50 of 20.8 μM against CD38 cyclase. (E/Z)-CCR-11 promotes increases in cellular NAD+ levels and interferon γ.
  • HY-P990037
    Erzotabart
    Inhibitor
    Erzotabart is an IgG1-kappa, anti-CD38 (ADP-ribosyl cyclase 1, cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, cADPR1) Homo sapiens monoclonal antibody. Erzotabart shows antineoplastic activity.